COMP <GO>
THC vs ABBV // EV/EBITDA & P/E VALUATION
Tenet Healthcare Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: THC 5
— ABBV 10
▲ EV/EBITDA & P/E VALUATION LEADER: THC
LAST: $273.25 (+0.99%) • MKT CAP: $21.79B
valuation
6.3x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (THC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | THC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.60% | 29.00% | -1.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.3x | 33.3x | -27.00 | THC | /valuation <GO> |
| Free Cash Flow Yield | 11.61% | 3.47% | +8.14 | THC | /fcf-yield <GO> |
| Operating Margin | 16.50% | 24.60% | -8.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 11.10% | 6.90% | +4.20 | THC | /net-margins <GO> |
| Revenue Growth (YoY) | 3.10% | 8.60% | -5.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.08 | 5.33 | -3.25 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 7.40% | -0.60 | THC | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.2 | 72.8 | -14.62 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.97 | 1.15 | -0.18 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 8.6x | 113.1x | -104.50 | THC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $21.79B | $513.86B | -$492.07B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | THC REV | ABBV REV | THC GROSS % | ABBV GROSS % | THC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.31B | $61.16B | 44.0% | 70.2% | $2.53B | $17.82B |
| FY 2024 | $20.68B | $56.33B | 44.0% | 70.0% | $1.12B | $17.83B |
| FY 2023 | $20.56B | $54.32B | 44.0% | 44.0% | $1.45B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
THC // BETA 0.97
ABBV // BETA 1.15